<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960724</url>
  </required_header>
  <id_info>
    <org_study_id>AK-2016-HHC1</org_study_id>
    <nct_id>NCT02960724</nct_id>
  </id_info>
  <brief_title>uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer</brief_title>
  <official_title>Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      uPAR PET/CT for Staging Advanced and Localised oral and oropharyngeal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the diagnostic value of uPAR-PET/CT for prognostication compared to the current
      imaging options (CT, MRI and ultrasound) by observer-blinded readings. The reference that
      will be used as &quot;gold standard&quot; is the pathological examination of the surgically removed
      tissues.

      The new imaging modality (uPAR-PET/CT) will be used in two separate groups of patients with
      head and neck cancer:

      Study I:

      Patients with oral cancer without clinical evidence of spread (OSCC in stage cN0)

      Study II:

      Patients with metastatic oral cancer (OSCC in stage cN +) and patients with metastatic
      oropharyngeal cancer (OPSCC in stage cN +).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of lymph node metastases that can be identified by means of uPAR PET / CT compared with the histological findings.</measure>
    <time_frame>Through study completion, an average of 1.5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the correlation between uPAR PET signal (quantified as SUVmax) and the immunohistochemical expression of uPAR evaluated by an H-score (intensity x the percentage of stained tumor tissues throughout the tumor margin).</measure>
    <time_frame>Through study completion, an average of 1.5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the correlation between tumor burden (assessed v.h.a. TNM staging) uPAR-PET signal (assessed as SUVmax) and the amount of uPAR metabolites in plasma.</measure>
    <time_frame>Through study completion, an average of 1.5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the lower detection limit of the amount of tumor tissue for uPAR-PET correlated with the histological H-score x tumor size (where tumor size is evaluated on the pathological preparation of pathologist)</measure>
    <time_frame>Through study completion, an average of 1.5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Oral Cancer</condition>
  <condition>Oropharyngeal Cancer</condition>
  <condition>Neoplasms</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Cancer of Mouth</condition>
  <condition>Neoplasms by Site</condition>
  <arm_group>
    <arm_group_label>68Ga-NOTA-AE105 PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before surgery and compared with the histological findings to evaluate uPAR PET/CT in staging of oral cancer and oropharyngeal cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>68Ga-NOTA-AE105 PET/CT</intervention_name>
    <description>One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.</description>
    <arm_group_label>68Ga-NOTA-AE105 PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand patient information and to give informed consent

          -  Not previously irradiated or operated on neck

          -  Operable disease

        Study I OSCC cN0 verified histologically by pathologic examination of biopsy

        Study II OSCC or OPSCC N + verified histologically by pathologic examination of biopsy

        Exclusion Criteria:

          -  Pregnancy

          -  Patients who are candidates for curative intentional radiation

          -  Patients who have had surgery or radiation therapy to the neck as this may alter the
             lymph drainage.

          -  Other diseases assessed by the investigator as basis for exclusion.

          -  Age under 18 or over 85 years

          -  Obesity&gt; 140 kg

          -  Allergy to 68Ga-NOTA-AE105
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Kjær, MD,DMSc,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirstine KS Karnovs, MD</last_name>
      <phone>+4526227128</phone>
      <email>Kirstine.kim.schmidt.karnov@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Kjær, MD,DMSc,PhD</last_name>
      <phone>+4535454011</phone>
      <email>akjaer@sund.ku.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Skovgaard D, Persson M, Brandt-Larsen M, Christensen C, Madsen J, Klausen TL, Holm S, Andersen FL, Loft A, Berthelsen AK, Pappot H, Brasso K, Kroman N, Højgaard L, Kjaer A. Safety, Dosimetry, and Tumor Detection Ability of (68)Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging. J Nucl Med. 2017 Mar;58(3):379-386. doi: 10.2967/jnumed.116.178970. Epub 2016 Sep 8.</citation>
    <PMID>27609788</PMID>
  </results_reference>
  <results_reference>
    <citation>Persson M, Skovgaard D, Brandt-Larsen M, Christensen C, Madsen J, Nielsen CH, Thurison T, Klausen TL, Holm S, Loft A, Berthelsen AK, Ploug M, Pappot H, Brasso K, Kroman N, Højgaard L, Kjaer A. First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics. 2015 Sep 13;5(12):1303-16. doi: 10.7150/thno.12956. eCollection 2015.</citation>
    <PMID>26516369</PMID>
  </results_reference>
  <results_reference>
    <citation>Persson M, Nedergaard MK, Brandt-Larsen M, Skovgaard D, Jørgensen JT, Michaelsen SR, Madsen J, Lassen U, Poulsen HS, Kjaer A. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma. J Nucl Med. 2016 Feb;57(2):272-8. doi: 10.2967/jnumed.115.161703. Epub 2015 Oct 1.</citation>
    <PMID>26429955</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Kirstine Karnov</investigator_full_name>
    <investigator_title>MD, PhD-student</investigator_title>
  </responsible_party>
  <keyword>Uroplasminogen Plasminogen Activator Receptor</keyword>
  <keyword>Oropharyngeal cancer</keyword>
  <keyword>oral cancer</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Neoplasms by Site</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

